[go: up one dir, main page]

AU2006904635A0 - Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus - Google Patents

Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus

Info

Publication number
AU2006904635A0
AU2006904635A0 AU2006904635A AU2006904635A AU2006904635A0 AU 2006904635 A0 AU2006904635 A0 AU 2006904635A0 AU 2006904635 A AU2006904635 A AU 2006904635A AU 2006904635 A AU2006904635 A AU 2006904635A AU 2006904635 A0 AU2006904635 A0 AU 2006904635A0
Authority
AU
Australia
Prior art keywords
recombinant
envelope glycoprotein
improved treatment
hcv virus
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006904635A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Filing date
Publication date
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of AU2006904635A0 publication Critical patent/AU2006904635A0/en
Priority to KR1020097005994A priority Critical patent/KR101500017B1/en
Priority to AU2007288129A priority patent/AU2007288129B2/en
Priority to CN200780036968.8A priority patent/CN101563362B/en
Priority to US12/438,657 priority patent/US8535686B2/en
Priority to EP07784854.7A priority patent/EP2061805B1/en
Priority to PCT/AU2007/001221 priority patent/WO2008022401A1/en
Priority to JP2009525853A priority patent/JP5674310B2/en
Priority to CA002661814A priority patent/CA2661814A1/en
Priority to US13/967,059 priority patent/US9598467B2/en
Priority to JP2014185095A priority patent/JP5999524B2/en
Abandoned legal-status Critical Current

Links

AU2006904635A 2006-08-25 2006-08-25 Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus Abandoned AU2006904635A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002661814A CA2661814A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein
EP07784854.7A EP2061805B1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein
AU2007288129A AU2007288129B2 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein
CN200780036968.8A CN101563362B (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein
US12/438,657 US8535686B2 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein
KR1020097005994A KR101500017B1 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein
PCT/AU2007/001221 WO2008022401A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein
JP2009525853A JP5674310B2 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein
US13/967,059 US9598467B2 (en) 2006-08-25 2013-08-14 Recombinant HCV E2 glycoprotein
JP2014185095A JP5999524B2 (en) 2006-08-25 2014-09-11 Recombinant HCVE2 glycoprotein

Publications (1)

Publication Number Publication Date
AU2006904635A0 true AU2006904635A0 (en) 2006-09-07

Family

ID=

Similar Documents

Publication Publication Date Title
WO2008049974A8 (en) Peptide vaccine for influenza virus
WO2009059325A8 (en) Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
IL200432A0 (en) Human antibodies against hepatitis c virus (hcv) uses thereof
WO2010047830A3 (en) Agents for hcv treatment
IL194978A (en) Process for producing a composition of viral particles comprising recombinant modified vaccinia virus ankara
IL192548A0 (en) Viral hepatitis treatment
ZA200804356B (en) Stabilizing formulations for recombinant viruses
ZA201009135B (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
IL194920A0 (en) Hepatitis c virus infection biomarkers
GB0718984D0 (en) Structure of the hepatitis C virus NS5A protein
SI2589602T1 (en) Development of dengue virus vaccine components
EP2061805A4 (en) RECOMBINANT HCV E2 GLYCOPROTEIN
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2008064072A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
ZA200701674B (en) Vaccine composition against Hepatitis C virus
WO2013033319A3 (en) A cluster of neutralizing antibodies to hepatitis c virus
AU2006904635A0 (en) Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus
WO2007092607A3 (en) Treatment of hemorrhagic viral infections using a tissue factor inhibitor
HUE026600T2 (en) Compositions and methods for the treatment of viral hepatitis
ZA200807552B (en) Recombinant mononegaviral virus vectors
HK1128033A (en) Recombinant hcv e2 glycoprotein
AU2006906282A0 (en) Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906090A0 (en) Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
IL176377A0 (en) Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
HK1125306A (en) Recombinant viral vaccine